(VIANEWS) – The NASDAQ opens in less than six hours and ImmunoGen‘s pre-market value is already 4.94% up.
ImmunoGen’s last close was $4.66, 29.71% below its 52-week high of $6.63.
The last session, NASDAQ ended with ImmunoGen (IMGN) falling 5.28% to $4.66. NASDAQ dropped 1.59% to $12,006.96, following the last session’s downward trend on what was an all-around bearish trend exchanging session.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.252.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.96%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 38.9% and a negative 47.1%, respectively.
ImmunoGen’s sales growth is 35.5% for the present quarter and negative 44% for the next.
Yearly Top and Bottom Value
ImmunoGen’s stock is valued at $4.66 at 04:27 EST, way below its 52-week high of $6.63 and way higher than its 52-week low of $3.10.
Year-on-year quarterly revenue growth declined by 16.4%, now sitting on 89.44M for the twelve trailing months.
More news about ImmunoGen (IMGN).